Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 7/20 | 1.00 |
| ▸ | EGFR | P00533 | 10/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | PDE5A | O76074 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.65 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.65 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | FADS1 | O60427 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17124151 | 0.86 | EGFR (0.84) | ABCG2EGFRPOLBKMT2AMEN1 | |
| SCHEMBL29116258 | 0.85 | ABCG2 (0.74) | ABCG2EGFRPOLBKMT2AMEN1 | |
| SCHEMBL18996627 | 0.83 | EGFR (1.00) | ABCG2EGFRPOLBKMT2AMEN1 | |
| SCHEMBL1192454 | 0.83 | EGFR (1.00) | ABCG2EGFRPOLBKMT2AMEN1 | |
| SCHEMBL6837339 | 0.82 | EGFR (1.00) | ABCG2EGFR | |
| SCHEMBL18349251 | 0.81 | EGFR (0.77) | ABCG2EGFRKMT2AMEN1ALDH1A1 | |
| SCHEMBL2099212 | 0.81 | ABCG2 (1.00) | ABCG2EGFRKMT2AMEN1KDM4E | |
| SCHEMBL3244621 | 0.80 | EGFR (1.00) | ABCG2EGFR | |
| SCHEMBL8871973 | 0.80 | EGFR (0.83) | ABCG2EGFRKMT2AMEN1NPC1 | |
| SCHEMBL4587413 | 0.80 | EGFR (0.83) | ABCG2EGFRKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | claimed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | claimed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | claimed |
| EP-0520722-B1 | Therapeutic preparations containing quinazoline derivatives | ZENECA LTD (GB) | 1996-12-27 | — | — | EP | claimed |
| EP-0520722-A1 | Therapeutic preparations containing quinazoline derivatives | ZENECA LIMITED (GB) | 1992-12-30 | — | — | EP | claimed |
| WO-2009070328-A1 | MODULATORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) PATHWAY FOR USE IN THE TREATMENT OR PREVENTION OF SUBSTANCE ABUSE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-06-04 | — | — | WO | disclosed |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | disclosed |
| EP-0520722-B1 | Therapeutic preparations containing quinazoline derivatives | ZENECA LTD (GB) | 1996-12-27 | — | — | EP | disclosed |
| EP-0520722-A1 | Therapeutic preparations containing quinazoline derivatives | ZENECA LIMITED (GB) | 1992-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | IRF3, PML, TPMT | ABCG2 311/4885EGFR 1445/4885POLB 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.